

VERIFY.

AGENCY OF SWEDEN

WE SUPPORT THE SUSTAINABLE DEVELOPMENT GOALS



Bioinvent International AB has received its own declaration SIS / TS 2: 2021 to SS-EN ISO 26000: 2021, verified according to SIS / TS 3: 2021, on 5th of November 2024 which shows the organization's social responsibility to maximize the contribution to sustainable development.

The credibility of the self-declaration and conformity with real conditions has been verified by VERIFY Agency of Sweden AB with accreditation number 10482 and is accredited by Swedac for verification for ISO / IEC 17029: 2019.

The self-declaration consists of the management's statement and the organization's answers to the questions in SIS / TS 2: 2021, which is based on SS-EN ISO 26000: 2021 Organizations' social responsibility - Guidance.



Akkred. nr. 10482

Verifiering

ISO/IEC 17029

Assessment and Statement

Bioinvent International AB, located in Lund Sweden, is doing its first verification in 2024. The scope of the verification covers the entire company, which has 115 employees and is listed on Nasdaq Stockholm Stock Exchange.

Bioinvent is a clinical stage biotech company that discovers and develops novel and first-in-class immune modulatory antibodies for cancer therapy. The company currently has five drug candidates in six ongoing clinical programs in phase 1/2 trials, for the treatment of haematological cancer and solid - tumors. The company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the company's fully integrated manufacturing unit.

The company's shared vision for its sustainability work is contained in the following statement: *"Bioinvent places great importance on sustainability. We work actively to integrate sustainability and reducing our overall environmental footprint in our daily routines"*.

During the verification process Bioinvent has proven that the organisation works actively to integrate sustainability and reduce its overall environmental footprint in its daily routines. Bioinvent's management and employees share a sense of pride in the work of developing novel and first-in-class immuno-modulatory antibodies for cancer therapy. Through the shared sense of purpose comes a high level of productivity and a clear commitment to reduce negative while enhancing Bioinvent's positive impacts.

The company actively engages with key stakeholders, including patient organizations, patients, employees, academic partners, owners, investors, and employer's organizations, ensuring their interests are considered in decision-making. A structured materiality analysis has been conducted to help prioritize stakeholder relevance and align operations with the UN Sustainable Development Goals (SDGs). It led to having strategically selected specific SDGs that align with its operations. The ESG group's work centers around defining and implementing an action plan to achieve the identified goals. Regular periodic reviews facilitate progress monitoring and alignment with sustainability objectives.

The verification process has concluded that Bioinvent adheres to the principles of social responsibility, sustainable development, and transparency, which are named in the statements compiled in the company's self-declaration.

VERIFY.

AGENCY OF SWEDEN

WE SUPPORT THE SUSTAINABLE DEVELOPMENT GOALS



Terms and Conditions

This statement must be renewed within twelve months from the date below. The statement may be revoked before the period of validity if facts have been added that show that the organization's sustainability has decreased.

When the self-declaration is communicated publicly, this must be done together with the verification body's statement.

Decisions in this matter have been made by the decision-maker Helena Wiktor, after a presentation by Impact Auditor, Boris Matijas.

Helena Wiktor, Decision Maker VERIFY Agency of Sweden AB
Lund, 2024-12-05

